Aerovate Therapeutics, Inc.
AVTE
$2.66
$0.083.10%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -31.21% | 44.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -63.22% | -33.46% | |||
| Operating Income | 63.22% | 33.46% | |||
| Income Before Tax | 66.90% | 34.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 66.56% | 34.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 66.56% | 34.46% | |||
| EBIT | 63.22% | 33.46% | |||
| EBITDA | 62.80% | 34.22% | |||
| EPS Basic | 66.26% | 34.71% | |||
| Normalized Basic EPS | 66.61% | 34.71% | |||
| EPS Diluted | 66.26% | 34.71% | |||
| Normalized Diluted EPS | 66.61% | 34.71% | |||
| Average Basic Shares Outstanding | -0.87% | 0.37% | |||
| Average Diluted Shares Outstanding | -0.87% | 0.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
